化合物简介
Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba, first published in 1998 and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.
基本信息
中文名称
沙芬酰胺
英文名称
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
中文别名
(S)-2-[[4-[(3-氟苯甲基)氧]苯甲基]氨基]丙酰胺
英文别名
(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide、(S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide、(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide、Safinamide
CAS号
133865-89-1
分子式
C17H19FN2O2
分子量
302.343
精确质量
302.143
PSA
64.35
LOGP
3.4593
编号系统
UNII
90ENL74SIG
物化性质
密度
1.189 g/cm3
沸点
476.7ºC at 760 mmHg
折射率
1.569
蒸汽压
2.98E-09mmHg at 25°C
